Tipsheet
What matters at India’s listed companies
Concalls · Software Platform · Mid cap

Honasa triples EBITDA, pays first dividend, sets five-year targets.

Q4 revenue rose 28% to ₹682 crore. The company is now setting ambitious five-year targets for growth and margins.

5 earlier stories on Honasa Consumer Ltd.
Mkt cap₹13,618 cr
P/E68.11×
ROE6.16%
Debt / eq.0.00
Div yld0.72%
3x / FY26 Full-year EBITDA growth versus the prior year.

What's new

  • Quarterly revenue rose 28% year-on-year to ₹682 crore, net profit ₹69 crore.
  • Full-year EBITDA tripled, driven by face wash and serums; a maiden ₹3 per share dividend was declared.
  • Management guided for high-teens revenue CAGR and a 500 bps EBITDA margin improvement over five years.

Why this matters

The first dividend signals cash generation is real, not just a revenue story. The five-year guidance is ambitious: high-teens growth requires doubling distribution from 200,000 to 500,000 outlets in a market crowded with competitors.

What we're watching

  • How the Dr. Sheth's integration performs after management flagged narrative inconsistencies.
  • Execution on the plan to expand distribution from 200,000 to 500,000 outlets.
  • Whether the high-teens growth assumption holds in a competitive beauty market.

The full read

Honasa's Q4 is solid. Revenue hit ₹682 crore, up 28%. The bigger story is the full year: EBITDA grew 200%. Management paid a first-ever ₹3 per share dividend. That's a real number. The call's substance was the forward view. The company is guiding for high-teens CAGR over five years and a 500 bps margin gain. To get there, distribution must scale from 200,000 to 500,000 outlets. Management flagged some confusion around Dr. Sheth's, which grew over 100%, but reaffirmed its plans. The growth math is aggressive for a competitive market.

Questions answered

What was the financial performance for the quarter and full year?
Q4 revenue was ₹682 crore, up 28% year-on-year, with a net profit of ₹69 crore. For the full year, revenue grew 20% and EBITDA tripled versus the prior year.
What did management guide for the next five years?
Management guided for a high-teens compound annual growth rate in revenue and a 500 basis point improvement in EBITDA margins over five years.
How did the individual brands perform?
Mamaearth delivered double-digit growth, The Derma Co leads in actives, and Dr. Sheth's grew over 100%. Management did note some inconsistencies in the narrative around the Dr. Sheth's acquisition.
What is the dividend and distribution plan?
Honasa declared its first-ever dividend of ₹3 per share. The company plans to expand its distribution network from 200,000 to 500,000 outlets over three to five years.
Mentioned: Honasa Consumer · Mamaearth · Dr. Sheth's · The Derma Co
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Honasa Consumer Ltd.

Software Platform
₹13,577 cr
P/E 67.91×

Latest quarter · Mar 2026

Sales₹657 cr
Net profit₹70 cr
Op. margin+11.8%
EPS₹2.13

Strength & growth

Debt / equity0.00×
Current ratio2.07×
Financials via Tijori — a research aid, not investment advice.HONASA on Tijori
  1. 21 May 2026 · 6:32 PM IST Honasa triples EBITDA, pays first dividend, sets five-year targets.
  2. 13d ago Honasa Consumer buys 58% of Fluence Pharma for ₹135 cr
  3. 46d ago Honasa's FY26 profit jumps 177% to ₹191 cr; maiden dividend of ₹3
  4. 46d ago Honasa confirms strong FY26 with 177% profit surge, maiden dividend
  5. 46d ago Honasa posts record Q4 revenue, doubles profit, declares maiden dividend